R7999 matching placebo, REGN7999
R7999-BTHAL-2350
Phase 2 small_molecule active
Quick answer
R7999 matching placebo, REGN7999 for Non-transfusion dependent beta-thalassemia (NTDT), Beta-thalassemia Resultant Iron overload (IOL) is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Non-transfusion dependent beta-thalassemia (NTDT), Beta-thalassemia Resultant Iron overload (IOL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active